Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG: First Berlin starts coverage with EUR 67.90 price target
DGAP-News: Deutsche Biotech Innovativ AG / Key word(s): Research Update CORPORATE NEWS Deutsche Biotech Innovativ AG: First Berlin starts coverage with EUR 67.90 price target Hennigsdorf, 9 September 2015 – With the publication of the first research report, First Berlin Equity Research GmbH is starting coverage of Deutsche Biotech Innovativ AG (“DBI”). First Berlin’s initial assessment gives the company’s share a ‘buy’ rating and sees the fair value of the share at EUR67.90. As strengths of the company, First Berlin analyst Simon Scholes emphasises, inter alia, DBI’s innovative development approach. As a starting point for the identification of new drug targets DBI uses the thorough analysis of the blood of diseased patients. Only afterwards a target-related drug is being developed. This differs strongly from the conventional approach, in which targets are identified in animals first, and by this raises the probability that a drug candidate proves to be efficacious in the human body at the end of the development process. First Berlin also takes a favourable view of the unique approach to treating sepsis with DBI’s lead product, the drug Adrecizumab, and DBI’s strategic patent portfolio, which protects DBI’s sepsis drug development until at least 2032. Pipeline with blockbuster potential The complete research study is available on Deutsche Biotech Innovativ AG’s website via the following link: Share split executed as planned About Deutsche Biotech Innovativ AG The preclinical and clinical studies are mainly carried out by project companies in which DBI AG holds a stake. Currently, DBI AG holds 26% of AdrenoMed AG (Agent: Adrecizumab), 25% of Oncoprevent GmbH (Agent: DB1RA), 100% of AngioBiomed GmbH (Agent: AB2302) and 50% of My Life Diagnostics GmbH (Diagnostic agent for urinary tract infection). Both members of DBI’s Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialising in the identification of blood biomarkers for treating serious illnesses. It was sold in 2009 for around EUR330 million. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). For more information, please contact: Deutsche Biotech Innovativ AG Kirchhoff Consult AG 2015-09-09 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
393387 2015-09-09 |